| Texto completo | |
| Autor(es): Mostrar menos - |
Grosche, Victoria Riquena
;
Souza, Leandro Peixoto Ferreira
;
Ferreira, Giulia Magalhaes
;
Guevara-Vega, Marco
;
Carvalho, Tamara
;
Silva, Romerio Rodrigues dos Santos
;
Batista, Karla Lilian Rodrigues
;
Abuna, Rodrigo Paolo Flores
;
Silva, Joao Santana
;
Calmon, Marilia de Freitas
;
Rahal, Paula
;
da Silva, Luis Claudio Nascimento
;
Andrade, Bruno Silva
;
Teixeira, Claudener Souza
;
Sabino-Silva, Robinson
;
Jardim, Ana Carolina Gomes
Número total de Autores: 16
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Viruses-Basel; v. 15, n. 9, p. 26-pg., 2023-09-01. |
| Resumo | |
The SARS-CoV-2 entry into host cells is mainly mediated by the interactions between the viral spike protein (S) and the ACE-2 cell receptor, which are highly glycosylated. Therefore, carbohydrate binding agents may represent potential candidates to abrogate virus infection. Here, we evaluated the in vitro anti-SARS-CoV-2 activity of two mannose-binding lectins isolated from the Brazilian plants Canavalia brasiliensis and Dioclea violacea (ConBR and DVL). These lectins inhibited SARS-CoV-2 Wuhan-Hu-1 strain and variants Gamma and Omicron infections, with selectivity indexes (SI) of 7, 1.7, and 6.5, respectively for ConBR; and 25, 16.8, and 22.3, for DVL. ConBR and DVL inhibited over 95% of the early stages of the viral infection, with strong virucidal effect, and also protected cells from infection and presented post-entry inhibition. The presence of mannose resulted in the complete lack of anti-SARS-CoV-2 activity by ConBR and DVL, recovering virus titers. ATR-FTIR, molecular docking, and dynamic simulation between SARS-CoV-2 S and either lectins indicated molecular interactions with predicted binding energies of -85.4 and -72.0 Kcal/Mol, respectively. Our findings show that ConBR and DVL lectins possess strong activities against SARS-CoV-2, potentially by interacting with glycans and blocking virus entry into cells, representing potential candidates for the development of novel antiviral drugs. (AU) | |
| Processo FAPESP: | 21/00603-3 - Análise do viroma de carrapatos coletados em animais silvestres |
| Beneficiário: | Paula Rahal |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 19/07784-3 - Estudo in vitro da ação de peptídeos sintéticos como antivirais contra CHIKV |
| Beneficiário: | Marilia de Freitas Calmon |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |